Acceptability

Singer Jordin Sparks Performs and Rep. Frankel and Rep. Hudson Honored at Global Down Syndrome Foundation’s May 9th AcceptAbility Gala in DC

Retrieved on: 
星期三, 四月 17, 2024
Narrative, CO, Congress, Marriott Marquis, Public policy, UnitedHealth Group, Lobbying, NIH, Acceptability, NCTA, Down syndrome, Member of Congress, Jan Adams, Research, PwC, American Express, SVP, Senior, Family, Regulatory affairs, Government, Pharmaceutical industry

“We are excited to highlight the extraordinary talents and gifts of people with Down syndrome at our AcceptAbility Gala.

Key Points: 
  • “We are excited to highlight the extraordinary talents and gifts of people with Down syndrome at our AcceptAbility Gala.
  • With GLOBAL’s leadership bringing together multiple stakeholders, the NIH Down syndrome research and medical care budget has increased by $338 million over the last six years.
  • During the gala, GLOBAL will honor 2024 GLOBAL Ambassador Isla Eager and her family from Arlington, Virginia and present the Rosa DeLauro & Tom Cole GLOBAL Advancement Awards to two self-advocates with Down syndrome.
  • The AcceptAbility Gala supports the Global Down Syndrome Foundation, funding life-changing research and lifesaving medical care for children and adults with Down syndrome.

Immunofoco Announces the Dual Approval of IND Applications by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors

Retrieved on: 
星期五, 二月 23, 2024
IIT, ESMO, ASCO, FDA, GEJ, Acceptability, ODD, Stomach, GC, Society, GI, Bone marrow, Patient, Clinical trial, CDE, Oncology, IND, Chinese, Epithelial cell adhesion molecule, Pharmaceutical industry

SHANGHAI, Feb. 22, 2024 /PRNewswire/ -- Immunofoco, a company dedicated to developing cell therapy products for solid tumors, announced a significant milestone, that following the approval by the CDE in China for the clinical trial application of IMC001, an EpCAM-targeting autologous CAR-T cell product for infusion, it also received the IND approval from the U.S. FDA, for the treatment of EpCAM-positive advanced gastrointestinal tumors, including but not limited to advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ).

Key Points: 
  • EpCAM serves as a biomarker for circulating tumor cells (CTCs), which is highly expressed in both primary and metastatic lesions of gastrointestinal tumors, while its expression in normal tissues is low.
  • IMC001, through targeting EpCAM, is the first CAR-T product utilizing the strategy of "curing the solid tumors by treating them as hematologic malignancies ".
  • She highlighted the significance of Immunofoco's achievement: securing dual IND approval for a second CAR-T product targeted for solid tumors in both the U.S. and China.
  • Targeting EpCAM shows great potential for CAR-T treatment of solid tumors as it is highly expressed in primary, metastatic and circulating tumor cells.

Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma

Retrieved on: 
星期一, 十一月 13, 2023
Uveal melanoma, Disease, Mum, OTCQB, Liver, Mortality, Patient, CMR, Kaplan–Meier estimator, Nivolumab, Ipilimumab, PET-CT, Springfield Armory M1A, Acceptability, Renewable energy, Pharmaceutical industry, Medical imaging

KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) ( NCT00986661 ).

Key Points: 
  • KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) ( NCT00986661 ).
  • mUM patients enrolled in this study received 1 or more cycles of PV-10 injection into 1 or more hepatic metastases.
  • Where indicated, standard of care immune checkpoint blockade (CB), as either monotherapy pembrolizumab or the combination of ipilimumab and nivolumab (IN), was also administered.
  • Dominic Rodrigues, Vice Chair of the Provectus’s Board of Directors, said, “Objective response is uncommon and complete metabolic response is rare in metastatic uveal melanoma.

Leidos Selected to Upgrade Hartsfield-Jackson Atlanta International Airport's Security Checkpoints

Retrieved on: 
星期二, 十二月 13, 2022
Travel, Hartsfield–Jackson Atlanta International Airport, Acceptability, AIT, CAP, ATL, Transport, Science, Culminating project, Security checkpoint, Annual report, TSE, NYSE, Intelligence, Division, LDOS, Government, TSA, Aviation, Risk, Engineering, ACL, Airport, Airline, Risk management, Leidos

RESTON, Va., Dec. 13, 2022 /PRNewswire/ -- Leidos (NYSE:LDOS), a FORTUNE 500 science and technology leader, today announced the company was selected by New-South Synergy to upgrade U.S. Transportation Security Administration (TSA) checkpoints at Hartsfield-Jackson Atlanta International Airport (ATL).

Key Points: 
  • RESTON, Va., Dec. 13, 2022 /PRNewswire/ -- Leidos (NYSE:LDOS), a FORTUNE 500 science and technology leader, today announced the company was selected by New-South Synergy to upgrade U.S. Transportation Security Administration (TSA) checkpoints at Hartsfield-Jackson Atlanta International Airport (ATL).
  • The upgrade will update security lanes at the Domestic Terminal Main Security Checkpoint with Leidos' Advanced Imaging Technology (AIT).
  • "The introduction of these new security technologies will enhance airport security operations, while improving the overall experience for Atlanta travelers."
  • To learn more about Leidos security detection solutions, with more than 24,000 products deployed across 120 countries, please visit www.leidos.com/security-detection .

uHoo Aura Secures RESET(TM) Accreditation

Retrieved on: 
星期二, 七月 26, 2022
GBP, Power, Carbon dioxide, Safety, Certification, Hoo Anthiya Uhoo Anthiya, Atmosphere, ESG, Green, IAQ, Goal, Brain, Environment, Electricity, Nitrogen dioxide, Carbon monoxide, Solution, LEED, WEEE, Risk management, Aura, Acceptability, Asphyxia, Dizziness, Motor vehicle, Consumer, Collaborative for High Performance Schools, Humidity, Sulfur dioxide, CEO, WELL, Adhesive, Fatigue, Software, Health, Solvent, Pressure regulator, Coal, Central nervous system, CO2, PM10, Singapore Green Plan 2012, Wood, Ammonia, Sound, Degenerative disease, Ozone, Hydrogen sulfide, CO, Headache, Allergy, Waste Electrical and Electronic Equipment Directive, Temperature, Commercial, Smoke, Atmosphere of Earth, Asthma, Electronic, Oxygen, Light, PM4, Property management, Heating, ventilation, and air conditioning, Social

uHoo Aura is the most comprehensive indoor environmental quality monitoring solution for businesses and commercial built environments.

Key Points: 
  • uHoo Aura is the most comprehensive indoor environmental quality monitoring solution for businesses and commercial built environments.
  • Along with the above parameters, uHoo Aura also monitors formaldehyde, PM1, PM4, and PM10, air pressure, light, and sound.
  • uHoo Aura being accredited by RESETas a Grade B monitorand uHoo being a RESET Accredited Data Provider serves as an addition to its current certifications and credentials including the Singapore Green Building Council's Green Building Product (GBP) certification, and the Waste from Electrical and Electronic Equipment or WEEE certification, which certifies that the uHoo Aura is environmentally-friendly in its design, manufacture, and use.
  • "The certifications and accreditations the uHoo Aura and the uHoo software have obtained are testimony to our commitment to continuous improvement and ensuring that our customers have the best and most environmentally responsible solution in their offices and buildings," says Dustin Jefferson S. Onghanseng, CEO of uHoo.

airSlate Expands signNow API Capabilities with Notarize Integration

Retrieved on: 
星期四, 五月 19, 2022
Software, Banking, Mobile, Wireless, Professional Services, Electronic Design Automation, Data Management, Technology, Security, Other Professional Services, Legal, Finance, Other Technology, Online, Education, API, ID, Acceptability, ENotary, Private law, HR, Disclosure, Solution, USD, BLS digital signature, RON, Facebook, Child, Paper, Organization, SignNow, E-sign, Adoption, LinkedIn, Twitter, CAGR, Software as a service, Growth, CRM, CEO, Mobile phone, Online shopping, Fine chemical, Notary

airSlate , a global leader in workflow automation solutions, announced a new integration within its signNow API with the market leader in Remote Online Notarization (RON), Notarize .

Key Points: 
  • airSlate , a global leader in workflow automation solutions, announced a new integration within its signNow API with the market leader in Remote Online Notarization (RON), Notarize .
  • The integration expands the capabilities of the signNow API, allowing users to legally notarize documents signed with electronic signature, all within a single application.
  • The Notarize feature within the signNow API is currently available for U.S. users, at a cost of $25 per notarization.
  • The signNow API integration is the latest of many that airSlate has sought out with Notarize, as the company implemented integrations within its US Legal Forms and pdfFiller solutions over the past year.